Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (219) 219
life sciences & biomedicine (217) 217
humans (210) 210
female (174) 174
oncology (139) 139
middle aged (104) 104
breast cancer (97) 97
adult (87) 87
breast neoplasms - drug therapy (86) 86
aged (84) 84
biological and medical sciences (82) 82
medical sciences (76) 76
breast neoplasms - pathology (63) 63
tumors (56) 56
cancer (48) 48
male (43) 43
gynecology. andrology. obstetrics (42) 42
mammary gland diseases (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (40) 40
care and treatment (37) 37
chemotherapy (37) 37
disease-free survival (34) 34
chemotherapy, adjuvant (33) 33
aged, 80 and over (32) 32
treatment outcome (31) 31
abridged index medicus (30) 30
breast neoplasms - mortality (29) 29
breast neoplasms - therapy (29) 29
anesthesiology (26) 26
medicine & public health (26) 26
prognosis (26) 26
analysis (23) 23
research (23) 23
antineoplastic agents (22) 22
breast neoplasms - metabolism (22) 22
clinical neurology (22) 22
clinical trials (22) 22
neurosciences & neurology (22) 22
pharmacology. drug treatments (21) 21
risk factors (21) 21
follow-up studies (20) 20
hematology, oncology and palliative medicine (20) 20
bone neoplasms - secondary (19) 19
general & internal medicine (19) 19
medicine, general & internal (19) 19
breast neoplasms - genetics (18) 18
neoplasm staging (18) 18
quality of life (18) 18
cyclophosphamide - administration & dosage (17) 17
drug therapy (17) 17
health aspects (17) 17
original reports (17) 17
antineoplastic agents - therapeutic use (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
doxorubicin - administration & dosage (16) 16
pain (16) 16
retrospective studies (16) 16
young adult (16) 16
patients (15) 15
proportional hazards models (15) 15
social sciences (15) 15
trastuzumab (15) 15
united states (15) 15
breast neoplasms - diagnostic imaging (14) 14
cancer therapies (14) 14
drug administration schedule (14) 14
metastasis (14) 14
breast neoplasms - diagnosis (13) 13
breast neoplasms - surgery (13) 13
psychotherapy (13) 13
survival (13) 13
breast neoplasms - complications (12) 12
diagnosis (12) 12
diphosphonates - therapeutic use (12) 12
kaplan-meier estimate (12) 12
obstetrics & gynecology (12) 12
paclitaxel - administration & dosage (12) 12
radiology, nuclear medicine & medical imaging (12) 12
randomized controlled trials as topic (12) 12
usage (12) 12
adolescent (11) 11
breast neoplasms - psychology (11) 11
developing countries (11) 11
fluorouracil - administration & dosage (11) 11
multiple tumors. solid tumors. tumors in childhood (11) 11
neoplasm metastasis (11) 11
pain medicine (11) 11
psychology (11) 11
receptor, erbb-2 - metabolism (11) 11
surveys and questionnaires (11) 11
survival analysis (11) 11
survival rate (11) 11
antineoplastic agents - adverse effects (10) 10
cancer patients (10) 10
chronic pain (10) 10
combined modality therapy (10) 10
neoadjuvant therapy (10) 10
prospective studies (10) 10
public, environmental & occupational health (10) 10
risk assessment (10) 10
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
by Eric P. Winer and Clifford Hudis and Harold J. Burstein and Antonio C. Wolff and Kathleen I. Pritchard and James N. Ingle and Rowan T. Chlebowski and Richard Gelber and Stephan B. Edge and Julie Gralow and Melody A. Cobleigh and Eleftherios P. Mamounas and Lori J. Goldstein and Timothy J. Whelan and Trevor J. Powles and John Bryant and Cheryl Perkins and Judy Perotti and Susan Braun and Amy S. Langer and George P. Browman and Mark R. Somerfield
Journal of clinical oncology, ISSN 0732-183X, 01/2005, Volume 23, Issue 3, pp. 619 - 629
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Tumors | Prognosis | Biomarkers, Tumor - analysis | Humans | Middle Aged | Risk Factors | Neoplasm Recurrence, Local | Receptors, Estrogen - analysis | Breast Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Receptors, Progesterone - analysis | Breast Neoplasms - pathology | Postmenopause | Female | Aged | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
by Goss, Paul E and Ingle, James N and Pritchard, Kathleen I and Robert, Nicholas J and Muss, Hyman and Gralow, Julie and Gelmon, Karen and Whelan, Tim and Whelan, Kate and Strasser-Weippl, Kathrin and Rubin, Sheldon and Sturtz, Keren and Wolff, Antonio C and Winer, Eric and Hudis, Clifford and Stopeck, Alison and Beck, J. Thaddeus and Kaur, Judith S and Tu, Dongsheng and Parulekar, Wendy R
The New England journal of medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 3, pp. 209 - 219
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Aromatase Inhibitors - administration & dosage | Recurrence | Triazoles - administration & dosage | Triazoles - adverse effects | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Secondary Prevention | Breast Neoplasms - drug therapy | Breast Neoplasms - prevention & control | Incidence | Nitriles - administration & dosage | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Postmenopause | Quality of Life | Female | Aged | Chemotherapy, Adjuvant | Nitriles - adverse effects | Breast Neoplasms - epidemiology | Care and treatment | Breast cancer | Middle aged women | Drug therapy | Health aspects | Inhibitor drugs | Estrogens | Endocrine therapy | Preventive medicine | Tamoxifen | Cancer therapies | Survival | Post-menopause | Quality of life | Osteoporosis | Chemotherapy | Fractures | Pain | Womens health | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
by Aapro, M and Abrahamsson, P.A and Body, J.J and Coleman, R.E and Colomer, R and Costa, L and Crinò, L and Dirix, L and Gnant, M and Gralow, J and Hadji, P and Hortobagyi, G.N and Jonat, W and Lipton, A and Monnier, A and Paterson, A.H.G and Rizzoli, R and Saad, F and Thürlimann, B
Annals of oncology, ISSN 0923-7534, 03/2008, Volume 19, Issue 3, pp. 420 - 432
metastases | bisphosphonates | bone | cancer | CTIBL | SRE | Bone | Bisphosphonates | Cancer | Metastases | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Tumors | Osteoporosis - prevention & control | Humans | Bone Neoplasms - secondary | Male | Lung Neoplasms - therapy | Bone Neoplasms - complications | Osteoporosis - etiology | Neoplasms - drug therapy | Prostatic Neoplasms - therapy | Breast Neoplasms - therapy | Neoplasms - complications | Bone Density - drug effects | Antineoplastic Agents - adverse effects | Diphosphonates - therapeutic use | Carcinoma - therapy | Female | Osteonecrosis - prevention & control | Kidney Neoplasms - therapy | Carcinoma - secondary | Practice Guidelines as Topic | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
by Coleman, R and Powles, T and Paterson, A and Gnant, M and Anderson, S and Diel, I and Gralow, J and von Minckwitz, G and Moebus, V and Bergh, J and Pritchard, K. I and Bliss, J and Cameron, D and Evans, V and Pan, H and Peto, R and Bradley, R and Gray, R and Early Breast Cancer Trialists' Collaborative Group (EBCTCG) and Novartis Pharmaceuticals and Early Breast Canc Trialists
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 10001, pp. 1353 - 1361
Internal Medicine | no | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Administration Schedule | Breast Neoplasms - pathology | Humans | Bone Density Conservation Agents - therapeutic use | Diphosphonates - therapeutic use | Breast Neoplasms - mortality | Female | Chemotherapy, Adjuvant | Breast Neoplasms - drug therapy | Clinical trials | Breast cancer | Drug therapy | Analysis | Adjuvant treatment | Cancer | Menopause | Mortality | Estrogen | Postmenopausal women | Metastasis | Studies | Bones | Health risk assessment | Cancer therapies | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Randomized controlled trial of the Valencia model of waking hypnosis plus CBT for pain, fatigue, and sleep management in patients with cancer and cancer survivors
by Mendoza, M.E and Capafons, A and Gralow, J.R and Syrjala, K.L and Suárez‐Rodríguez, J.M and Fann, J.R and Jensen, M.P
Psycho-oncology (Chichester, England), ISSN 1057-9249, 11/2017, Volume 26, Issue 11, pp. 1832 - 1838
waking hypnosis | fatigue | pain | cancer | oncology | insomnia | Psychology, Multidisciplinary | Social Sciences | Life Sciences & Biomedicine | Psychology | Social Sciences, Biomedical | Oncology | Biomedical Social Sciences | Science & Technology | Cancer Survivors | Sleep Initiation and Maintenance Disorders - etiology | Hypnosis - methods | Humans | Middle Aged | Pain Management - methods | Fatigue - etiology | Sleep Initiation and Maintenance Disorders - therapy | Depression | Male | Treatment Outcome | Neoplasms - psychology | Neoplasms - complications | Fatigue - therapy | Pain - complications | Aged, 80 and over | Adult | Cognitive Therapy | Female | Aged | Sleep Initiation and Maintenance Disorders - psychology | Cancer survivors | Care and treatment | Behavioral health care | Sleep | Pain | Insomnia | Analysis | Clinical trials | Psychotherapy | Fatigue | Cancer | Intervention | Cognitive therapy | Treatment needs | Survivor | Sleep problems | Cognitive behavioral therapy | Clinical research | Efficacy | Behavior modification | Cancer therapies | Evidence-based medicine | Randomized controlled trials | Psychological distress | Hypnosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002
by Eric P. Winer and Clifford Hudis and Harold J. Burstein and Rowan T. Chlebowski and James N. Ingle and Stephen B. Edge and Eleftherios P. Mamounas and Julie Gralow and Lori J. Goldstein and Kathleen I. Pritchard and Susan Braun and Melody A. Cobleigh and Amy S. Langer and Judy Perotti and Trevor J. Powles and Timothy J. Whelan and George P. Browman
Journal of clinical oncology, ISSN 0732-183X, 08/2002, Volume 20, Issue 15, pp. 3317 - 3327
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Humans | Evidence-Based Medicine | Breast Neoplasms - drug therapy | Enzyme Inhibitors - therapeutic use | Randomized Controlled Trials as Topic | Aromatase Inhibitors | Disease-Free Survival | Breast Neoplasms - enzymology | Breast Neoplasms - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Survival Analysis | Postmenopause | Female | Chemotherapy, Adjuvant | Expert Testimony | Nitriles - therapeutic use | Triazoles - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Abstract ES5-3: Late recurrence in ER-positive breast cancer
by Gralow, J
Cancer research (Chicago, Ill.), ISSN 0008-5472, 02/2019, Volume 79, Issue 4 Supplement, pp. ES5-3 - ES5-3
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy
by Moore, Halle C.F and Unger, Joseph M and Phillips, Kelly-Anne and Boyle, Frances and Hitre, Erika and Porter, David and Francis, Prudence A and Goldstein, Lori J and Gomez, Henry L and Vallejos, Carlos S and Partridge, Ann H and Dakhil, Shaker R and Garcia, Agustin A and Gralow, Julie and Lombard, Janine M and Forbes, John F and Martino, Silvana and Barlow, William E and Fabian, Carol J and Minasian, Lori and Meyskens, Frank L and Gelber, Richard D and Hortobagyi, Gabriel N and Albain, Kathy S and POEMS S0230 Investigators and POEMS/S0230 Investigators
The New England journal of medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 10, pp. 923 - 932
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Primary Ovarian Insufficiency - chemically induced | Pregnancy | Disease-Free Survival | Regression Analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Breast Neoplasms - mortality | Female | Primary Ovarian Insufficiency - prevention & control | Chemotherapy, Adjuvant | Goserelin - adverse effects | Goserelin - therapeutic use | Gonadotropin-Releasing Hormone - agonists | Pregnancy Rate | Complications and side effects | Chemotherapy | Breast cancer | Dosage and administration | Ovaries | Research | Goserelin | Risk factors | Cancer | Medical research | Follicle-stimulating hormone | Sensitivity analysis | Menopause | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Cancer therapies | Survival | Patients | Post-menopause | Reproductive status | Womens health | Fertility | Infertility | Gonadotropin-releasing hormone | Reproductive system | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
by Edith A. Perez and Vera J. Suman and Nancy E. Davidson and George W. Sledge and Peter A. Kaufman and Clifford A. Hudis and Silvana Martino and Julie R. Gralow and Shaker R. Dakhil and James N. Ingle and Eric P. Winer and Karen A. Gelmon and Bernard J. Gersh and Allan S. Jaffe and Richard J. Rodeheffer
Journal of clinical oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 8, pp. 1231 - 1238
Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Medical sciences | Tumors | Cyclophosphamide - administration & dosage | Prognosis | Humans | Risk Factors | Receptor, ErbB-2 - metabolism | Survival Rate | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Ventricular Dysfunction, Left - chemically induced | Heart Failure - drug therapy | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Breast Neoplasms - complications | Fluorouracil - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Heart - drug effects | Female | Heart Failure - chemically induced | Trastuzumab | Doxorubicin - administration & dosage | Index Medicus | trastuzumab | paclitaxel | adjuvant | breast cancer | cyclophosphamide | doxorubicin | HER2 | cardiac safety
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text 18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer
by W. B. Eubank and D. A. Mankoff and J. Takasugi and H. Vesselle and J. F. Eary and T. J. Shanley and J. R. Gralow and A. Charlop and G. K. Ellis and K. L. Lindsley and M. M. Austin-Seymour and C. P. Funkhouser and R. B. Livingston
Journal of clinical oncology, ISSN 0732-183X, 08/2001, Volume 19, Issue 15, pp. 3516 - 3523
Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Medical sciences | Tumors | Fluorodeoxyglucose F18 - pharmacokinetics | Mediastinal Neoplasms - secondary | Prevalence | Prospective Studies | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Breast Neoplasms - metabolism | Sensitivity and Specificity | Adult | Breast Neoplasms, Male - diagnostic imaging | Female | Retrospective Studies | Breast Neoplasms - diagnostic imaging | Radiopharmaceuticals - pharmacokinetics | Lymphatic Metastasis | Mediastinal Neoplasms - diagnostic imaging | Breast Neoplasms, Male - metabolism | Image Processing, Computer-Assisted | Biopsy | Breast Neoplasms - pathology | Aged | Tomography, Emission-Computed | Breast Neoplasms, Male - pathology | Mediastinal Neoplasms - metabolism | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights